Search the Newsreel

Are Investors Undervaluing Genworth Financial (GNW) Right Now?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends …

Genworth Financial (NYSE: GNW) details Q2 2026 results and $129M stock buybacks

Is Genworth Financial Inc (GNW) Overvalued After Q2 2026 Earnings? EPS at $0.12 with GF Score of 63/100

Earnings Flash (GNW) Genworth Financial, Inc. Reports Q2 Revenue $1.90B

Genworth Financial Announces Second Quarter 2026 Results

Strategic Highlights Strong capital returns from Enact, with $103M received in the quarter Repurchased $62M of shares in the quarter; $918M since program inception through June 30, 2026 CareScout delivered 1,459 matches1 in the quarter, with continued progress expanding the network Care Assurance Worksite …

Genworth Financial (GNW) Earnings Date and Reports 2026

What’s Driving GLSI Stock Today?

Greenwich LifeSciences (GLSI) stock rose over 7% after providing an update on its delayed Form 10-K filing, easing Nasdaq listing concerns. The delay was attributed to accounting adjustments related to stronger-than-expected patient enrollment in its Phase III breast cancer trial. With the filing nearing …

Impressive Earnings May Not Tell The Whole Story For Envision Greenwise Holdings (HKG:1783)

Genworth Financial Inc Revenue Breakdown – NYSE:GNW

Envision Greenwise Clears Key Earnings Hurdle in Hong Kong Acquisition Deal

Genworth Financial (GNW.US) will release its earnings report after market close on August 5.

Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock

Greenwich LifeSciences CEO Snehal Patel recently purchased 2,200 shares of company stock for a total of $29,555. These transactions occurred on July 28 and July 29, 2026, at prices between $13.10 and $13.59 per share. The insider buying comes as the stock has declined …

Understanding the Setup: (GLSI) and Scalable Risk

This article provides an AI-generated analysis of Greenwich Lifesciences Inc. (GLSI), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes the importance …

Form 4 Greenwich Lifesciences Inc For: 30 July By Investing.com

This article from Investing.com is a brief report on a Form 4 filing for Greenwich Lifesciences Inc. dated July 30. It provides the stock symbol GLSI and notes a -3.71% change. The content primarily consists of the title and symbol, suggesting it's an automated …

Aureus Greenway Changes Ticker to PUSA Ahead of Proposed Merger

Additional Considerations Required While Assessing Envision Greenwise Holdings' (HKG:1783) Strong Earnings

GLSI|Greenwich Lifesciences Inc|Price:12.720|Chg%:-0.730

This article provides a comprehensive financial overview of Greenwich Lifesciences Inc. (GLSI), including its stock performance, market capitalization, and detailed financial statements. It highlights key financial indicators like EPS, Revenue, and Net Profit across various quarters, along with a summary of its balance sheet …

Genworth Financial (GNW) Expected to Post Quarterly Earnings on Wednesday

Greenwing Resources Converts 776,785 Options Into Ordinary Shares at $0.08

Greenwing Resources Issues 776,785 Shares on Exercise of Unlisted Options

Peter Stanley Wright Exercises 714,285 Options at Greenwing Resources, Increasing Stake to 17.1 Million Shares

Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Greenwich Lifesciences Inc (GLSI), rating its overall financial score at 6.92 out of 385 in its industry. While its financial status is robust, the company's operating efficiency is low, and key financial data for several categories …

Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 2,500 Shares

Greenwich LifeSciences (NASDAQ: GLSI) CEO adds 3,600 shares in open-market buys

Greenwich LifeSciences (NASDAQ: GLSI) CEO and CFO, Snehal Patel, recently purchased 3,600 shares of common stock in open-market transactions. These purchases occurred on July 23 and July 24, 2026, at prices of $13.14 and $12.88 per share respectively, increasing his direct holdings to over …

Aureus Greenway Holdings Inc. Revenue Breakdown – NASDAQ:PUSA

Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for Greenwich Lifesciences Inc (GLSI). It states that no dividend data is available, as a total of $0.00 has been distributed in dividends over the past five years. The page also displays current stock prices and …

Greenwich Lifesciences Inc (GLSI) Institutional Confidence

This article analyzes the institutional confidence score for Greenwich Lifesciences Inc (GLSI), noting its current score of 3.00, ranking 192 out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 19.42% quarter-over-quarter, reaching 11.38%. It also details …

Enwell Energy plc Revenue Breakdown – LSE:ENW

Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History

This article provides detailed financial information on Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company focused on cancer immunotherapies. It covers the company's stock performance, key financial metrics, news, analyst ratings, and a company overview highlighting its lead product candidate GP2 for breast cancer. …

Greenwich LifeSciences Gets UK Clearance to Expand Breast Cancer Trial

Greenwich LifeSciences has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to expand its Phase III clinical trial for GP2 into the United Kingdom. This expansion will allow more breast cancer patients to participate in the trial, which focuses on …

UK approval could add 5-10 sites to Greenwich LifeSciences trial

Greenwich LifeSciences (NASDAQ: GLSI) announced UK regulatory approval to expand its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy to prevent breast cancer recurrences. This approval will allow the company to add 5-10 UK sites to the existing 170-180 sites in the US and …

Greenwich LifeSciences gains UK approval for breast cancer trial By Investing.com

Greenwich LifeSciences (NASDAQ:GLSI) has received UK regulatory approval to expand its Phase III clinical trial FLAMINGO-01 into the United Kingdom, adding 5-10 UK sites. The trial evaluates GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences, and is being conducted in collaboration with The …

Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer Trial

Greenwich LifeSciences has received UK regulatory approval to expand its Phase III FLAMINGO-01 breast cancer trial into the United Kingdom, allowing for the addition of 5-10 new clinical sites. This expansion builds on existing sites in the US and Europe and is a collaborative …

Brokers Set Expectations for GLSI Q1 Earnings

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

Greenwich LifeSciences, Inc. announced regulatory approval to expand its Phase III clinical trial, FLAMINGO-01, into the United Kingdom. This expansion will add 5-10 UK sites in collaboration with The Royal Marsden, aiming to offer participation to the UK's large population. The trial evaluates GLSI-100, …

What Makes Genworth Financial (GNW) a Strong Momentum Stock: Buy Now?

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of …